New Standard When HER2+ Breast Cancer Isn ' t Cleared New Standard When HER2+ Breast Cancer Isn ' t Cleared

' Practice-changing ' results support adjuvant trastuzumab emtansine in patients with HER2+ early stage breast cancer who have residual disease following surgery.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news